



PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1702

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Bernward SCHÖLKENS et al. ) Group Art Unit: 1617  
)  
Application No.: 09/645,556 ) Examiner: J. Kim  
)  
Filed: August 25, 2000 ) Confirmation No.: 3278  
)  
For: PHARMACEUTICAL )  
FORMULATIONS AND USE )  
THEREOF IN THE PREVENTION )  
OF STROKE, DIABETES AND/OR )  
CONGESTIVE HEART FAILURE )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Supplemental Information Disclosure Statement is being filed together with a Request for Continued Examination.

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

The following applies to the non-English language documents:

DE 199 13 528 A1: An English language abstract of the document is enclosed.

JP 10081633: An English language abstract of the document is enclosed.

EP 0 079 022: An English language abstract of the document is enclosed. This document also has English language claims at cols. 16-18.

WO 01/78747: An English language abstract appears on the cover page and an English language abstract is enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: September 13, 2005

By:   
Steven J. Scott  
Reg. No. 43,911

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

PATENT &amp; TRADEMARK

## Complete if Known

Application Number 09/645,556  
 Filing Date August 25, 2000  
 First Named Inventor Bernward SCHÖLKENS  
 Address Unit 1617  
 Examiner Name J. Kim  
 Attorney Docket Number 02481.1702

## U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		H1286	02/1994	Eisman et al.	
		5,130,333	07/1992	Pan et al.	
		5,140,012	08/1992	McGovern et al.	
		5,157,025	10/1992	Aberg et al.	
		5,217,958	06/1993	Patel	
		5,298,497	03/1994	Tschollar et al.	
		5,461,039	10/1995	Tschollar et al.	
		5,508,272	04/1996	Robl	
		5,593,971	01/1997	Tschollar et al.	
		5,622,985	04/1997	Olukotun et al.	
		5,674,893	10/1997	Behounek et al.	
		5,691,375	11/1997	Behounek et al.	
		6,180,660	01/2001	Whitney et al.	
		2005/0101658	05/2005	Scholkens et al.	

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		JP 10081633	03/1998			English Abstract
		DE 199 13 528	06/2000			English Abstract
		EP 0 079 022	05/1983			English Abstract
		EP 0 401 705	12/1990			
		EP 0 457 514	11/1991			
		EP 0 459 453	12/1991			
		EP 0 461 548	12/1991			
		EP 0 508 665	10/1992			
		EP 0 671 170	09/1995			
		EP 0 671 171	09/1995			
		EP 0 738 512	10/1996			
		WO 90/05531	05/1990			
		WO 92/20673	11/1992			
		WO 94/11369	05/1994			

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet



2

of

2

Complete if Known

Application Number	09/645,556
Filing Date	August 25, 2000
First Named Inventor	Bernward SCHOLKENS
Art Unit	1617
Examiner Name	J. Kim
Attorney Docket Number	02481.1702



## FOREIGN PATENT DOCUMENTS

		WO 95/26188	05/1995			
		WO 95/13063	05/1995			
		WO 99/11260	03/1999			
		WO 99/09967	03/1999			
		WO 00/18395	04/2000			
		WO 00/45818	08/2000			
		WO 00/67737	11/2000			
		WO 01/11038	02/2001			
		WO 01/15744	03/2001			
		WO 01/76632	10/2001			
		WO 01/76573	10/2001			
		WO 01/78747	10/2001			English Abstract

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		Office Action dated April 19, 2005, in application no. 10/694,001	
		Paul N. Durrington, "Diabetic dyslipidaemia," Bailliere's Clinical Endocrinology and Metabolism, Vol. 13, No. 2, pp. 265-278 (1999)	
		The GISEN Group, "Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy," THE LANCET, Vol. 349, pp. 1857-1863 (1997)	
		Alistair S. Hall et al., "Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study," THE LANCET, Vol. 349, pp. 1493-1497 (1997)	
		Robert A. Kreisberg, "Diabetic Dyslipidemia," American Journal of Cardiology, Vol. 82, (12A), pp. 67U-73U (1998)	
		Jonathan Leor, et al., "Aspirin and Mortality in Patients Treated With Angiotensin-Converting Enzyme Inhibitors," Journal of the American College of Cardiology, Vol. 33, No. 7, pp. 1920-1925 (1999)	
		The Merck Manual, 14 <sup>th</sup> Ed., published by Merck & Co., Inc. (NJ) pp. 488-489 (1982)	
		Wu Ning et al., "Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril," Chinese Medical Journal, 110(8), pp. 602-606 (1997)	
		The PEACE Trial Investigators, "Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease," N Engl J Med, 351:20, pp. 2058-2068 (2004)	
		Bertram Pitt, M.D., "ACE Inhibitors for Patients with Vascular Disease without Left Ventricular Dysfunction-May They Rest in PEACE?," N Engl J Med, 351:20, pp. 2115-2117 (2004)	

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.